

IN THE CLAIMS:

*Please amend the listing of claims to read as follows:*

Claims 1-24. (cancelled)

25. (new) A treatment device for *in situ* treatment of an abnormal physiological formation containing blood under pressure, such as an aneurysm or a leaky repaired formation, in a mammal, optionally a human, said abnormal physiological formation having an internal wall defining an internal volume, the treatment device comprising at least one expandable implant, said at least one expandable implant being expandable from a first relatively small implant configuration configured for delivery of said implant to a second relatively large implant configuration, said at least one implant in said relatively large implant configuration providing support for only a portion of the internal wall of the abnormal physiological formation, said at least one implant comprising an expandable polymeric foam, wherein said at least one implant is deliverable into the abnormal physiological formation in said first relatively small implant configuration.

26. (new) An abnormal physiological formation treatment device as in claim 25, wherein said polymeric foam is a reticulated elastomeric matrix.

27. (new) An abnormal physiological formation treatment device as in claim 25, wherein said polymeric foam is a reticulated biodurable elastomeric matrix.

28. (new) An abnormal physiological formation treatment device according to claim 25, wherein said polymeric foam is formed in a relatively large configuration, is subsequently compressed for delivery to said volume for expansion to said first expanded configuration.

29. (new) An abnormal physiological formation treatment device according to claim

25, wherein said implant comprises a biodurable member configured for use in an abnormal physiological formation sac, an endo leak , or a perigraft space between an endograft and an abnormal physiological formation.

30. (new) An abnormal physiological formation treatment device according to claim 25, wherein said polymeric foam defines, through said polymeric foam, a fluidic path positioned, configured and dimensioned to provide a flow of body fluid such as blood to said internal wall of said abnormal physiological formation sufficient to promote cellular ingrowth and proliferation at said internal wall, when said device is contained within said internal volume.

31. (new) An abnormal physiological formation treatment device according to claim 25, wherein said polymeric foam comprises a plurality of interconnected struts which bear against at least a portion of said internal wall to support said portions against which said interconnected struts bear.

32. (new) An abnormal physiological formation treatment device according to claim 25, further comprising a second expandable implant, said second expandable implant being expandable from a relatively small configuration to a relatively large configuration, said second implant comprising an expandable polymeric foam, wherein the second implant is deliverable into the abnormal physiological formation in said relatively small implant configuration, said expandable implant and said second expandable implant being configured and dimensioned to leave portions of said internal wall out of contact with said implants.

33. (new) An abnormal physiological formation treatment device according to claim 25, further wherein a projecting portion of said implant is configured, dimensioned and positioned to be grasped by a surgeon to facilitate positioning of the implant.

34. (new) An abnormal physiological formation treatment device according to claim 25, wherein the implant is formed essentially entirely of a reticulated biodurable

elastomeric matrix.

35. (new) An abnormal physiological formation treatment device according to claim 25, further comprising an element made of a material different from said compressible foam.

36. (new) An abnormal physiological formation treatment device according to claim 35, wherein said polymeric foam is a reticulated elastomeric matrix, and said element made of a material different from said compressible foam is bendable.

37. (new) An abnormal physiological formation treatment device as in claim 36, wherein said element made of a material different from said reticulated elastomeric matrix is strut-like.

38. (new) An abnormal physiological formation treatment device as in claim 37 wherein said strut has a materials characteristic suitable to perform a support function.

39. (new) An abnormal physiological formation treatment device as in claim 35, wherein said strut is a support rod.

40. (new) An abnormal physiological formation treatment device according to claim 25, wherein the materials characteristic of said implant are such that said implant may be manipulated into a suitable position.

41. (new) An abnormal physiological formation treatment device according to claim 40, wherein said implant is substantially relaxed when fully deployed.

42. (new) An abnormal physiological formation treatment device according to claim 25, wherein said implant has an elongated configuration.

43. (new) An abnormal physiological formation treatment device according to claim 42, wherein said elongated configuration is substantially round in cross-section.

44. (new) An abnormal physiological formation treatment device as in claim 19 wherein said implant is substantially configured as a cylinder.
45. (new) An abnormal physiological formation treatment device as in claim 43 wherein said implant is substantially configured as a bullet shape with a blind hollow volume.
46. (new) An abnormal physiological formation treatment device according to claim 25, wherein an irregular cutout has been removed from said implant.
47. (new) An abnormal physiological formation treatment device as in claim 25, wherein said abnormal physiological formation is in fluidic communication with an artery and further comprising a sheath placed in the lumen of the artery.
48. (new) An abnormal physiological formation treatment device as in claim 25, wherein said implant is ribbed in configuration.
49. (new) An abnormal physiological formation treatment device as in claim 25 wherein said implant has a skeletal structure comprising support members and defining open spaces.
50. (new) An abnormal physiological formation treatment device as in claim 25, wherein said polymeric foam defines a continuous interconnected void.
51. (new) An abnormal physiological formation treatment device as in claim 25, wherein said polymeric foam defines pores having a density between 14 and 60 pores per centimeter.
52. (new) An abnormal physiological formation treatment device as in claim 51, wherein said polymeric foam is a reticulated biodurable elastomeric matrix.
53. (new) An abnormal physiological formation treatment device as in claim 25, wherein said polymeric foam defines pores having a density between 16 and 32 pores

per centimeter.

54. (new) An abnormal physiological formation treatment device as in claim 25, wherein said polymeric foam comprises a biodurable elastomeric polyurethane matrix comprising a polycarbonate polyol component and an isocyanate component.

55. (new) An abnormal physiological formation treatment device as in claim 25, wherein said biodurable reticulated elastomeric matrix comprising a polycarbonate, polysiloxane, polyurethane, hydrocarbon, or mixture or copolymers, thereof.

56. (new) An abnormal physiological formation treatment device according to claim 25, wherein said foam comprises growth factors.

57. (new) An abnormal physiological formation treatment device according to claim 25, wherein said foam comprises elastin to promote clot formation.

58. (new) An abnormal physiological formation treatment device according to claim 25, wherein said foam comprises a radiopaque substance.

59. (new) A treatment device for an abnormal physiological formation containing blood under pressure, such as an aneurysm or a leaky repaired formation, for in situ treatment of said abnormal physiological formation in a mammal, optionally a human, said abnormal physiological formation having an internal wall defining an internal volume, the treatment device comprising at least one expandable implant, said at least one expandable implant being expandable from a first relatively small implant configuration to a second relatively large implant configuration, said at least one implant in said relatively large implant configuration providing support for at least a portion of the internal wall of the abnormal physiological formation, said at least one implant comprising an expandable elastomeric matrix, wherein said at least one implant is deliverable into the abnormal physiological formation in said first relatively small implant configuration, wherein said elastomeric matrix defines, through said

elastomeric matrix, a fluidic path positioned, configured and dimensioned to provide a flow of blood to said internal wall of said abnormal physiological formation sufficient to promote cellular ingrowth and proliferation at said internal wall, when said device is contained within said internal volume.

60. (new) An abnormal physiological formation treatment device as in claim 59, wherein said elastomeric matrix is a reticulated elastomeric matrix.

61. (new) A treatment device for an abnormal physiological formation containing blood under pressure, such as an aneurysm or a leaky repaired formation, for in situ treatment of said abnormal physiological formation in a mammal, optionally a human, said abnormal physiological formation having an internal wall defining an internal volume, the treatment device comprising at least one expandable implant, said at least one expandable implant being expandable from a first relatively small implant configuration to a second relatively large implant configuration, said at least one implant in said relatively large implant configuration providing support for at least a portion of the internal wall of the abnormal physiological formation, said at least one implant comprising an expandable polymeric foam, wherein said implant has a surface with elevations and depressions structured to allow a flow of blood to promote cellular metabolism at the surface of said internal wall.

62. (new) A method of making a treatment device for treating an abnormal physiological formation containing blood under pressure, such as an aneurysm or a leaky repaired formation in a mammal, optionally a human, said abnormal physiological formation having an internal wall defining an internal volume, the method of making comprising forming a polymeric foam comprising a biodurable elastomeric polyurethane matrix, wherein the biodurable elastomeric polyurethane matrix comprises a polycarbonate polyol component and an isocyanate component formed by polymerizing, cross-linking and foaming to form a resultant foam, followed by reticulation of the resultant foam.